Topic: influenza

Seqirus says it is phasing delivery of its flu vaccine Fluad to the U.K. ahead of the peak season, though pharmacists have reported a lack of supply.

Seqirus published data showing that cell-derived flu viruses matched better with circulating strains than egg-based counterparts.

Vaxart touted phase 2 data for its oral flu vaccine candidate in a trial against Sanofi's market-leading Fluzone.

Through an ongoing "challenge" study, FluGen hopes to see whether the nasal vaccine can fight off the flu virus that doesn't match its own.

Xofluza only showed numerical reduction in time to symptom improvement compared with Tamiflu in complicated flu patients.

Having missed two flu seasons, AZ has swapped out FluMist's H1N1 component, which was linked to low efficacy that led to previous CDC rejections.

After examining GSK's internal safety reports, The BMJ suggests serious safety signal had emerged for Pandemrix but was not made public.

Here is some other vaccine news of note for the week.

A group of pediatric experts has recommended injected vaccines over AstraZeneca's FluMist for the upcoming season.

CSL's flu vaccine unit Seqirus posted $1.09 billion in sales during its 2018 fiscal year and turned in its first-ever profit.